Panther Therapeutics Closes Oversubscribed $5.4M Series A Round, Expands Board Of Directors, As Company Prepares To Initiate First Clinical Trial Of Novel Localized Treatment Of Pancreatic Cancer
Panther Therapeutics Closes Oversubscribed $5.4M Series A Round, Expands Board Of Directors, As Company Prepares To Initiate First Clinical Trial Of Novel Localized Treatment Of Pancreatic Cancer
06/17/21, 11:49 AM
Location
cambridgeMoney raised
$5.4 million
Round Type
series a
PanTher Therapeutics (PanTher), a privately held oncology company revolutionizing the treatment of solid tumors through direct, localized, and sustained delivery of proven and novel therapeutic agents, announces today that it has closed an oversubscribed $5.4M Series A round led by Catalyst Health Ventures (CHV), with participation by Angel Physicians Fund (APF) and other notable investors. The Series A round brings the total amount raised by the company to $7.4M.
Company Info
Location
cambridge, maryland, united states
Additional Info
PanTher Therapeutics (PanTher) is a privately held oncology company revolutionizing cancer care with a proprietary treatment platform designed to enhance therapeutic response while minimizing side effects. PanTher is currently investigating the platform for the treatment of solid tumors, and the company is gearing up to initiate its first clinical trial for its lead indication, pancreatic cancer. The technology at the foundation of PanTher’s proprietary treatment was developed at the Massachusetts Institute of Technology (MIT) and was subsequently in-licensed by PanTher. The platform empowers oncologists to treat patients with life-threatening cancer by unlocking a drug’s full potential through direct, sustained treatment at the tumor site. This unique targeting capability positions PanTher to take on the deadliest and most acute cancers. For more information, visit www.panthertx.com.